Status:
COMPLETED
Impact of Antiretroviral Therapy on Cardiac Biomarkers
Lead Sponsor:
University of California, Davis
Collaborating Sponsors:
California HIV/AIDS Research Program
Conditions:
HIV Infections
Eligibility:
All Genders
18-69 years
Brief Summary
Cardiovascular risk appears to be linked to some degree with inflammation. HIV medications have been linked with cardiovascular risk. In this study we will be measuring levels of chemicals in the body...
Detailed Description
With the advent of antiretroviral therapy, death due to opportunistic diseases have seen a major decline among patients with HIV. However, several antiretroviral medications, in particular protease in...
Eligibility Criteria
Inclusion
- Patients with a CD4 count between 200-400 planning on initiating antiretrovirals.
Exclusion
- Pregnancy,
- Recent discontinuation of an antiretroviral within the past 30 days,
- Active intravenous drug use,
- Acute febrile illness with temperature \> 100 F,
- Diagnosis or symptoms of acute infection within the past 30 days,
- Opportunistic infection or surgical procedure within the past 60 days,
- Myocardial infarction within the last 30 days,
- Renal disease (CKD Stages 3-5), and
- Unstable liver disease.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00641888
Start Date
March 1 2008
End Date
October 1 2014
Last Update
July 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Davis
Sacramento, California, United States, 95817